Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BDNF | P23560 | 3/20 | 0.32 |
| ▸ | PTN | P21246 | 2/20 | 0.32 |
| ▸ | MDK | P21741 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23777366 | 0.86 | MAPK1 (0.42) | MAPK1 | |
| SCHEMBL23777340 | 0.86 | BDNF (0.33) | MAPK1BDNFPTNMDK | |
| SCHEMBL23026436 | 0.84 | MAPK1 (0.46) | MAPK1BDNFPTNMDK | |
| SCHEMBL24294567 | 0.80 | LMNA (0.43) | — | |
| SCHEMBL16392569 | 0.80 | BDNF (0.32) | MAPK1BDNFPTNMDK | |
| SCHEMBL18875803 | 0.78 | MAPK1 (0.39) | MAPK1BDNFPTNMDK | |
| SCHEMBL17283423 | 0.77 | MAPK1 (0.38) | MAPK1BDNFPTNMDK | |
| SCHEMBL26879463 | 0.75 | BDNF (0.32) | BDNFPTNMDK | |
| SCHEMBL17283392 | 0.74 | BDNF (0.33) | MAPK1BDNFPTNMDK | |
| SCHEMBL17283436 | 0.73 | KEAP1 (0.40) | BDNFPTNMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-03-03 | — | — | US | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3873530-A1 | THERAPEUTIC METHODS | Genevant Sciences GmbH (CH) | 2021-09-08 | — | — | EP | disclosed |
| EP-3873486-A1 | BIVALENT TARGETED CONJUGATES | Arbutus Biopharma Corporation (CA) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062323-A1 | BIVALENT TARGETED CONJUGATES | ERBB2, PCNA, MRE11 | MAPK1 4708/4885BDNF 3953/4885PTN 3171/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | MAPK1 4626/4885BDNF 3834/4885PTN 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.